Trial Profile
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; CV 301 (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Bavarian Nordic
- 19 Feb 2022 The trial has discontinued as per the results presented at the 2022 Genitourinary Cancers Symposium
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.